Phase 3 Chronic Spontaneous Urticaria Clinical Trials
6 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–6 of 6 trials
Recruiting
Phase 3
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
Chronic Spontaneous Urticaria
Novartis Pharmaceuticals100 enrolled65 locationsNCT05677451
Recruiting
Phase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Celldex Therapeutics1,370 enrolled20 locationsNCT07256392
Recruiting
Phase 2Phase 3
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria (CSU)
Beijing InnoCare Pharma Tech Co., Ltd.344 enrolled30 locationsNCT07378527
Recruiting
Phase 3
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Chronic Spontaneous Urticaria (CSU)
Novartis Pharmaceuticals400 enrolled114 locationsNCT06868212
Recruiting
Phase 3
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Taizhou Mabtech Pharmaceutical Co.,Ltd392 enrolled1 locationNCT06365879
Recruiting
Phase 3
A Study of Efficacy and Safety of TLL-018 in CSU Participants
Chronic Spontaneous Urticaria
Hangzhou Highlightll Pharmaceutical Co., Ltd436 enrolled1 locationNCT06396026